Eli Lilly announced results from a head-to-head study comparing dulaglutide (Trulicity) to insulin glargine (Lantus; Sanofi Aventis) for hemoglobin A1c (HbA1C) reduction in patients with type 2 diabetes. The study was presented at the 75th American Diabetes Association (ADA) Scientific Sessions in Boston, MA.
The randomized, open-label, parallel-arm 26-week study enrolled 789 patients with type 2 diabetes inadequately controlled on metformin and/or a sulfonylurea primarily from China and also Korea, Mexico, and Russia. Patients received dulaglutide 0.75mg, dulaglutide 1.5mg, or insulin glargine and had an average baseline HbA1C of 8.36%; they continued to receive background treatment of metformin and/or a sulfonylurea during the study.
Both doses of dulaglutide showed superiority to insulin glargine in HbA1C reduction (-1.7% dulaglutide 1.5mg, -1.32% dulaglutide 0.75mg, -1.15% insulin glargine) and significantly more patients reached the recommended HbA1C target of <7% with dulaglutide (65% dulaglutide 1.5mg, 54% dulaglutide 0.75mg, 41% insulin glargine). Patients treated with dulaglutide 1.5mg and 0.75mg also lost an average of 1.51kg and 0.88kg, respectively, while patients treated with insulin glargine gained on average 0.96kg.
Dulaglutide is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist indicated as adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes.
For more information call (800) 545-5979 or visit Trulicity.com.